Valuation: Cerenome, Inc.

Market Cap 1.24Cr 1.11Cr 1.03Cr 93.23L 1.74Cr 118.42Cr 1.77Cr 12Cr 4.9Cr 62Cr 4.67Cr 4.57Cr 196.11Cr P/E 2026 *
-0.34x
P/E 2027 * -0.66x
Enterprise Value 1.24Cr 1.11Cr 1.03Cr 93.23L 1.74Cr 118.42Cr 1.77Cr 12Cr 4.9Cr 62Cr 4.67Cr 4.57Cr 196.11Cr EV / Sales 2026 *
3.35x
EV / Sales 2027 * 0.65x
Free-Float
97.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Cerenome, Inc.

1 day-4.27%
1 week-7.65%
Current month-16.04%
1 month-21.11%
3 months-59.01%
6 months-76.21%
Current year-87.74%
1 week 1.51
Extreme 1.51
1.84
1 month 1.48
Extreme 1.485
2.28
Current year 1.48
Extreme 1.485
15.32
1 year 1.48
Extreme 1.485
18.88
3 years 1.48
Extreme 1.485
69.5
5 years 1.48
Extreme 1.485
810
10 years 1.48
Extreme 1.485
3,99,377.5
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Exercice

Director

1,842 0.0268%
01/10/26 Exercice

Director

1,842 0.0268%
01/10/26 Exercice

Chairman

1,842 0.0268%
Change 5-day change 1-year change 3-year change Capi.($)
-4.27%-7.65%-89.79%-93.78% 1.24Cr
+0.88%+1.18%+40.64%+74.91% 6.47TCr
-0.26%+7.23%+11.14%+74.78% 5.48TCr
+0.47%+5.10%+8.22%+101.52% 5.35TCr
-2.06%+2.51%+24.07%+50.98% 4.6TCr
-1.79%+0.49%+19.32%+122.77% 4.29TCr
-1.65%+3.34%+237.56%+819.04% 4.01TCr
-2.26%-2.06%+15.38%+45.14% 3.35TCr
+0.22%-4.77%+26.59%+0.55% 2.4TCr
+12.10%+18.47%+55.14%+45.58% 2.37TCr
Average +0.14%+1.65%+34.83%+124.15% 3.83TCr
Weighted average by Cap. +0.12%+2.59%+45.92%+149.87%

Financials

2026 *2027 *
Net sales 37.2L 33.26L 30.77L 27.86L 52.14L 35Cr 53L 3.7Cr 1.46Cr 19Cr 1.4Cr 1.37Cr 59Cr 1.91Cr 1.71Cr 1.58Cr 1.43Cr 2.68Cr 182.11Cr 2.73Cr 19Cr 7.54Cr 95Cr 7.18Cr 7.03Cr 301.58Cr
Net income -3.26Cr -2.92Cr -2.7Cr -2.44Cr -4.57Cr -310.47Cr -4.65Cr -32Cr -13Cr -162.39Cr -12Cr -12Cr -514.16Cr -1.91Cr -1.7Cr -1.58Cr -1.43Cr -2.67Cr -181.29Cr -2.72Cr -19Cr -7.5Cr -95Cr -7.15Cr -7Cr -300.22Cr
Net Debt - -
Projected Income Statement - Annual - Cerenome, Inc.
Logo Cerenome, Inc.
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
Employees
28
Date Price Change Volume
27/26/27 $1.570 -4.27% 74,045
23/26/23 $1.640 -6.29% 62,575
22/26/22 $1.750 +1.16% 43,136
21/26/21 $1.730 +2.98% 53,821
20/26/20 $1.680 +1.82% 76,921
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cerenome, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.640USD
Average target price
27.75USD
Spread / Average Target
+1,592.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerenome, Inc.
  1. Stock Market
  2. Stocks
  3. CNSY Stock